Matsuzaki Juntaro, Suzuki Hidekazu
Center for Preventive Medicine, Keio University Hospital, Tokyo 160-0016, Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
J Clin Med. 2015 Aug 6;4(8):1566-77. doi: 10.3390/jcm4081566.
MiR-221 and miR-222 (miR-221/222) are well-studied oncogenic microRNAs that are frequently upregulated in several types of human tumors, such as esophageal adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma. In these cancers, silencing miR-221/222 could represent a novel anti-tumor approach to inhibit tumor growth and metastasis. On the other hand, miR-221/222 also play onco-suppressive roles in cholangiocarcinoma and gastrointestinal stromal tumors (GISTs). Here we will review the roles of miR-221/222 in digestive systems and their possibility as prognostic and therapeutic tools.
微小RNA-221和微小RNA-222（miR-221/222）是经过充分研究的致癌性微小RNA，在几种人类肿瘤中经常上调，如食管腺癌、胃腺癌、结肠腺癌、肝细胞癌和胰腺导管腺癌。在这些癌症中，使miR-221/222沉默可能代表一种抑制肿瘤生长和转移的新型抗肿瘤方法。另一方面，miR-221/222在胆管癌和胃肠道间质瘤（GIST）中也发挥着肿瘤抑制作用。在此，我们将综述miR-221/222在消化系统中的作用及其作为预后和治疗工具的可能性。
